Home » Topics » BioWorld Science

BioWorld Science
RSS

Celsion advances PLACCINE DNA-based vaccine platform to proof-of-concept NHP studies

May 11, 2022

MALT1 promotes glioblastoma pathogenesis and emerges as a potential therapeutic target

May 11, 2022

Type 2 diabetes getting precision medicine makeover

May 11, 2022

Targeting BCL10-MALT1 interaction blocks ABC-DLBCL xenograft tumor growth

May 11, 2022

Accent Therapeutics discloses METTL3 inhibitors

May 11, 2022

AC Immune synthesizes MAPT aggregation inhibitors

May 11, 2022

Proxygen and collaborators present new compounds for cancer

May 11, 2022

Chinese researchers describe new ADCs for cancer

May 11, 2022

Rheinische Friederich-Wilhelms-Universitaet Bonn discloses MRGPRX4 agonists

May 11, 2022

TL-532 induces life-long antitumor autovaccination and cross-immunity against unrelated cancers

May 11, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...